The study was conducted across 5 Norwegian Rheumatology Departments and included 796 RA patients, 162 PsA patients and 211 patients with a diagnosis of AS. All patients were on an anti-TNF treatment regimen of infliximab, etanercept or adalimumab +/- methotrexate (MTX). The primary outcome was the number of patients still on therapy at one year known as the adherence to therapy. RA was used as the reference group and within each diagnostic group the adherence to anti-TNF monotherapy versus TNF+MTX was compared.
The relative risk for withdrawal from TNF+MTX versus anti-TNF monotherapy was 0.54 for RA patients, 0.49 for PsA patients and 0.83 for AS patients, demonstrating that combination treatment strategy of anti-TNF+MTX worked better than anti-TNF monotherapy in patients with RA and PsA. Although the crude one-year overall drug adherence rates for anti-TNF therapy were superior in patients with PsA and AS compared to RA, after adjusting for age, gender and concomitant MTX, the adherence to anti-TNF treatment were similar in patients with RA and PsA whereas the adherence to anti-TNF treatment was superior in patients
Contact: Mia Gannedahl
European League Against Rheumatism